Two experts will present clinical data supplemented by a series of case presentations with interactive polling and discussion for healthcare providers to better understand the latest updates, guidelines, and strategies to identify patients and implement treatment decisions for their post‐transplant acute myeloid leukemia (AML) patients.
This program is intended for clinicians who manage patients with post‐transplant acute myeloid leukemia (AML). This includes community and institution based medical oncologists, hematologists/oncologists and their team members.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Practice Point Communications. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material activity for a maximum of AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHYSICIAN ASSISTANTS, NURSE PRACTITIONERS, NURSES AND OTHER HEALTHCARE PROFESSIONALS
Physician Assistants (AAPA), Nurse Practitioners (AANP), and Nurses (ANCC) can count ACCME activities certified for AMA PRA Category 1 Credit™ for professional credit reporting purposes. All healthcare professionals, other than physicians, should inquire with their respective certifying or licensing boards to confirm.
MITIGATION OF CONFLICT OF INTEREST
The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24 months. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.
DISCLOSURE OF RELATIONSHIPS WITH INELIGIBLE COMPANIES
The University is committed to providing its learners with high-quality CME activities that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The University requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all relationships with ineligible companies within the last 24 months. All relevant relationships are thoroughly vetted and mitigated according to the ACCME and University’s policy. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
The faculty and planners reported the following financial relationships, or relationships to products or devices, they have with ineligible companies (commercial interests) related to the content of this CME activity.
DISCLOSURES
The speakers and planning committee members listed below have stated they have no relevant relationships to disclose.
Susan Tyler, Ph.D
Bruce Gebhardt, MD
Robert Ellis, MD
Heather Muskopf
Nirupama Mulherkar
Jill Valone
Martin Stevens
FACULTY DISCLOSURES
Keith Pratz, MD
Consultant: AbbVie, Agios, Astellas, BMS/Celgene, Jazz Pharmaceuticals, Servier
Research Support: AbbVie, Agios, Astellas, Millenium
Daniel Pollyea,MD
Advisory Board: AbbVie, Aprea, Arcellx, Astellas, AstraZeneca, BeiGene, BergenBio, Bristol Myers Squibb, Foghorn, Genentech, Jazz, Karyopharm, Kiadis, Kura, Magenta, Novartis, Qihan, Ryvu, Syndax, Syros, Zentalis
Consultant: AbbVie, Genentech, Gilead Sciences, Karyopharm, Novartis, Syros, Takeda
Recipient of Research Funding: AbbVie, Bristol Myers Squibb, Karyopharm, Teva
Gail Roboz, MD
Consultant, Advisory Board, Data and Safety Monitoring Committee: AbbVie, Agios, Amgen, Astellas,
AstraZeneca, Bluebird Bio, Blueprint Medicines, Bristol Myers Squibb, Catamaran, Celgene, GlaxoSmithKline,
Helsinn, Janssen, Jasper Therapeutics, Jazz, Mesoblast, Novartis, Pfizer, Roche, Syndax, Takeda(IRC Chair)
Research Support: Janssen
DISCLAIMER
The opinions expressed during this activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati and Practice Point Communications. The information is presented for the purpose of advancing the attendees’ professional development.
PRIVACY POLICY
The University of Cincinnati and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Cincinnati and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The University of Cincinnati and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
HARDWARE/SOFTWARE REQUIREMENTS
Computer:
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Software/Browser:
- Windows 7 or above running Internet Explorer 10 or above.
- MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Mobile Device:
- Any Apple iPad or iPad Mini running iOS 7.1 or above.
- Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by independent educational grants from Astellas and Bristol Myers Squibb